Eko raises $20M Series B for its AI powered in-clinic and at-home cardiac monitoring platform which includes devices that combine digital stethoscope and ECG
Jasmine Pennic / hitconsultant.net :
Context & Ripple Effects
Eko's $20M Series B slots into a funding lane opened by AliveCor, whose AI platform for flagging abnormal heart conditions drew a $30M round led by Omron back in 2017. Where AliveCor started from mobile ECG hardware, Eko is attacking the same problem from the stethoscope side, pairing its digital stethoscope with ECG devices so one exam captures both sounds and electrical signals.
The bet paid forward: fourteen months later Eko closed a $65M Series C to expand remote disease screening programs, and its abnormality-detecting algorithm moved through clinical trials on top of an already-cleared Eko Core attachment.
First-order effects
- Eko gets the runway to push its abnormality-detecting algorithm through clinical trials and toward clearance, converting the FDA-approved Eko Core attachment into a diagnostic product rather than a listening aid.
- AliveCor's mobile-monitor franchise now faces a rival whose device sits inside clinicians' existing workflow — the stethoscope around their necks.
Second-order effects
- Capital follows the category: AliveCor raised its own $65M Series E led again by Omron, while Cardiologs and Cleerly pulled in rounds for AI heart-condition detection and imaging respectively — cardiac AI becoming a multi-front funding race across auscultation, rhythm, and imaging.
- Payers and health systems gain competing vendors for at-home cardiac screening, letting procurement pressure split the market between stethoscope-based and patch/mobile-based monitoring.
Third-order effects
- If hardware-plus-algorithm platforms keep out-raising single-purpose devices, routine primary-care exams become data capture points, with the stethoscope and ECG repositioned as sensors feeding screening algorithms rather than standalone diagnostic tools.
The trend: Cardiac monitoring is consolidating around venture-backed hardware-plus-algorithm platforms, with each successive round pushing screening from the cardiology clinic into primary care and the home.